Primary sources
These are the main regulatory and clinical records behind the current evidence pages.
- FDA briefing document: BPC-157-related bulk drug substances
- FDA briefing document: TB-500-related bulk drug substances
- FDA: certain bulk substances that may present significant safety risks
- ClinicalTrials.gov: BPC-157 hamstring-injury study
- FDA prescribing information: PRIALT (ziconotide)
- Randomized trial: intrathecal ziconotide for severe chronic nonmalignant pain
- STEP 9 randomized trial: semaglutide in obesity and knee osteoarthritis
- Meta-analysis: collagen supplementation and knee osteoarthritis
- Meta-analysis: analgesic efficacy of collagen peptide in knee osteoarthritis
- Randomized trial: low-molecular-weight collagen peptides in knee osteoarthritis
- Early trial: ARA-290 in type 2 diabetes and neuropathic symptoms
- Phase 2b trial: cibinetide in sarcoidosis-associated small-fiber loss
- CDC clinical practice guideline for prescribing opioids for pain
Source list last reviewed: August 11, 2026.